## YaleNewHaven**Health**

**Smilow Cancer Hospital** 



## **Grand Rounds**

Join us in person for lunch!

TUESDAY, December 13, 12:00pm <u>Zoom</u> Access

Hosted by the Cancer Immunology Research Program

The determinants of effective anti-tumor immunity in kidney cancer



## David Braun, MD, PhD

Assistant Professor of Medicine, Pathology, and Urology; Goodman and Gilman Yale Scholar

**Needs:** Need for awareness of kidney cancer immunobiology and for understanding determinants of immunotherapy response and resistance.

**Objectives:** Understand the genomic landscape of kidney cancer, Describe the unique microenvironment of kidney cancer. Understand the potential benefit of personalized immunotherapy approaches





There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Braun- Consulting: Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, AbbVie. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.